Molecular targets of curcumin for cancer therapy: An updated review

Tumor Biology

Volumn 37, Issue 10, 2016, Pages 13017-13028

  Kasi, Pandima Devi ^a   Tamilselvam, Rajavel ^a   Skalicka Woźniak, Krystyna ^b   Nabavi, Seyed Fazel ^c   Daglia, Maria ^d   Bishayee, Anupam ^e   Pazoki Toroudi, Hamidreza ^f   Nabavi, Seyed Mohammad ^c  

^a ALAGAPPA UNIVERSITY   (India)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF PAVIA   (Italy)

^e Larkin Health Science Institute   (United States)

^f IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anticancer; Curcumin; Polyphenol; Turmeric

Indexed keywords

CURCUMIN; CYCLIN DEPENDENT KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; RAS PROTEIN; STAT PROTEIN; TRANSCRIPTION FACTOR AP 1; ANTINEOPLASTIC AGENT;

AKT SIGNALING; BETA CATENIN SIGNALING; CANCER CHEMOTHERAPY; CANCER INHIBITION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; P53 PATHWAY; PRIORITY JOURNAL; RAS SIGNALING; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; WNT SIGNALING; ANIMAL; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CURCUMIN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85027941490     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-5183-y     Document Type: Review

References (114)

1. Ruddon RW. Cancer biology. New York: OxfordUniversity Press; 2007.
2. Russo M, Russo GL, Daglia M, Kasi PD, Ravi S, Nabavi SF, et al. Understanding genistein in cancer: the ”good” and the ”bad” effects: a review. Food Chem. 2016;196:589-600.
3. Saranath D, Khanna A. Current status of cancer burden: global and Indian scenario. Biomed Res J. 2014;1(1):1-5.
4. Devi KP, Rajavel T, Nabavi SF, Setzer WN, Ahmadi A, Mansouri K, et al. Hesperidin: a promising anticancer agent from nature. Ind Crop Prod. 2015;76:582-9.
5. Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25(9):2097-116.
6. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11): 1148-59.
7. Taby R, Issa JPJ. Cancer epigenetics. CA Cancer J Clin. 2010;60(6):376-92.
8. Perera FP. Environment and cancer: who are susceptible? Science. 1997;278(5340):1068-73.
9. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci. 1995;92(12):5258-65.
10. Boffetta P. Human cancer from environmental pollutants: the epidemiological evidence. Mutat Res Genet Toxicol Environ Mutagen. 2006;608(2):157-62.
11. Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012;226(2):352-64.
12. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36(3):131-49.
13. Curti V, Capelli E, Boschi F, Nabavi SF, Bongiorno AI, Habtemariam S, et al. Modulation of human miR-17-3p expression by methyl 3-O-methyl gallate as explanation of its in vivo protective activities. Mol Nutr Food Res. 2014;58(9):1776-84.
14. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;75(3):311-35.
15. Fulda S. Modulation of apoptosis by natural products for cancer therapy. Planta Med. 2010;76(11):1075-9.
16. Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, et al. Anti-cancer natural products isolated fromchinesemedicinal herbs. ChinMed. 2011;6(1):27.
17. Cragg GM, Kingston DG, Newman DJ. Anticancer agents from natural products. Boca Raton: CRC Press; 2011.
18. Demain AL, Vaishnav P. Natural products for cancer chemotherapy. Microb Biotechnol. 2011;4(6):687-99.
19. Mehta RG, Murillo G, Naithani R, Peng X. Cancer chemoprevention by natural products: how far have we come? Pharm Res. 2010;27(6):950-61.
20. Nabavi SM, Nabavi SF, Eslami S, Moghaddam AH. In vivo protective effects of quercetin against sodium fluoride-induced oxidative stress in the hepatic tissue. Food Chem. 2012;132(2):931-5.
21. Nabavi SF, Nabavi SM, Habtemariam S, Moghaddam AH, Sureda A, Jafari M, et al. Hepatoprotective effect of gallic acid isolated from Peltiphyllum peltatum against sodium fluoride-induced oxidative stress. Ind Crop Prod. 2013;44:50-5.
22. Nabavi SM, Marchese A, Izadi M, Curti V, Daglia M, Nabavi SF. Plants belonging to the genus Thymus as antibacterial agents: from farm to pharmacy. Food Chem. 2015;173:339-47.
23. Alinezhad H, Azimi R, Zare M, Ebrahimzadeh MA, Eslami S, Nabavi SF, et al. Antioxidant and antihemolytic activities of ethanolic extract of flowers, leaves, and stems of Hyssopus officinalis L. Var. Angustifolius. Int J Food Prop. 2013;16(5): 1169-78.
24. Nabavi SF, Nabavi SM, Mirzaei M, Moghaddam AH. Protective effect of quercetin against sodium fluoride induced oxidative stress in rat’s heart. Food Funct. 2012;3(4):437-41.
25. Nabavi SF, Nabavi SM, Ebrahimzadeh MA, Eslami B, Jafari N. In vitro antioxidant and antihemolytic activities of hydroalcoholic extracts of Allium scabriscapum Boiss. & Ky. Aerial parts and bulbs. Int J Food Prop. 2013;16(4):713-22.
26. Nabavi SF, Russo GL, Daglia M, Nabavi SM. Role of quercetin as an alternative for obesity treatment: you are what you eat! Food Chem. 2015;179:305-10.
27. Di Lorenzo A, Nabavi SF, Sureda A, Moghaddam AH, Khanjani S, Arcidiaco P, et al. Antidepressive-like effects and antioxidant activity of green tea and GABA green tea in a mouse model of post-stroke depression. Mol Nutr Food Res. 2016;60:566-79.
28. Nabavi SF, Nabavi SM, Moghaddam AH, Naqinezhad A, Bigdellou R, Mohammadzadeh S. Protective effects of Allium paradoxum against gentamicin-induced nephrotoxicity in mice. Food Funct. 2012;3(1):28-9.
29. Nabavi SF, Nabavi SM, Ebrahimzadeh MA, Jafari N, Yazdanpanah S. Biological activities of freshwater algae, Spirogyra singularis Nordstedt. J Aquat Food Prod Technol. 2013;22(1):58-65.
30. Nabavi SF, Daglia M, Moghaddam AH, Habtemariam S, Nabavi SM. Curcumin and liver disease: from chemistry to medicine. Compr Rev Food Sci Food Saf. 2014;13(1):62-77.
31. Ghosh S, Banerjee S, Sil PC. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. Food Chem Toxicol. 2015;83:111-24.
32. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41(1):40-59.
33. Darvesh AS, Carroll RT, Bishayee A, Novotny NA, Geldenhuys WJ, Van der Schyf CJ. Curcumin and neurodegenerative diseases: a perspective. Expert Opin Investig Drugs. 2012;21(8):1123-40.
34. Darvesh AS, Aggarwal BB, Bishayee A. Curcumin and liver cancer: a review. Curr Pharm Biotechnol. 2012;13(1):218-28.
35. Sinha D, Biswas J, Sung B, Aggarwal BB, Bishayee A. Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr Drug Targets. 2012;13(14):1799-819.
36. Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol. 2015;35(Suppl): S276--304.
37. Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm. 2010;343(9):489-99.
38. Oyagbemi AA, Saba AB, Ibraheem AO. Curcumin: from food spice to cancer prevention. Asian Pac J Cancer Prev. 2009;10(6): 963-7.
39. Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res. 2008;52(9): 1010-30.
40. Thangapazham RL, Sharma A, Maheshwari RK. Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J. 2006;8(3):E443-E9.
41. Shehzad A, Lee YS. Molecular mechanisms of curcumin action: signal transduction. Biofactors. 2013;39(1):27-36.
42. Tuorkey M. Curcumin a potent cancer preventive agent: mechanisms of cancer cell killing. Interv Med Appl Sci. 2014;6(4):139-46.
43. Schneider C, Gordon ON, Edwards RL, Luis PB. Degradation of curcumin: from mechanism to biological implications. J Agric Food Chem. 2015;63(35):7606-14.
44. Ahmed K, Li Y, McClements DJ, Xiao H. Nanoemulsion-and emulsion-based delivery systems for curcumin: encapsulation and release properties. Food Chem. 2012;132(2):799-807.
45. Tønnesen HH, Karlsen J. Studies on curcumin and curcuminoids. Z Lebensm Unters Forsch. 1985;180(5):402-4.
46. Tønnesen HH, Másson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm. 2002;244(1): 127-35.
47. Leung MH, Colangelo H, Kee TW. Encapsulation of curcumin in cationic micelles suppresses alkaline hydrolysis. Langmuir. 2008;24(11):5672-5.
48. Liu A, Lou H, Zhao L, Fan P. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal. 2006;40(3):720-7.
49. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 2007;330(1): 155-63.
50. Wang X, Jiang Y, Wang Y-W, Huang M-T, Ho C-T, Huang Q. Enhancing anti-inflammation activity of curcumin through O/W nanoemulsions. Food Chem. 2008;108(2):419-24.
51. Yu H, Huang Q. Enhanced in vitro anti-cancer activity of curcumin encapsulated in hydrophobically modified starch. Food Chem. 2010;119(2):669-74.
52. Borrin TR, Georges EL, Moraes IC, Pinho SC. Curcumin-loaded nanoemulsions produced by the emulsion inversion point (EIP) method: an evaluation of process parameters and physicochemical stability. J Food Eng. 2016;169:1-9.
53. Li J, Lee IW, Shin GH, Chen X, Park HJ. Curcumin-Eudragit® E PO solid dispersion: a simple and potent method to solve the problems of curcumin. Eur J Pharm Biopharm. 2015;94:322-32.
54. Patil S, Choudhary B, Rathore A, Roy K, Mahadik K. Enhanced oral bioavailability and anticancer activity of novel curcumin loaded mixed micelles in human lung cancer cells. Phytomedicine. 2015;22(12):1103-11.
55. John PC, Mews M, Moore R. Cyclin/Cdk complexes: their involvement in cell cycle progression and mitotic division. Protoplasma. 2001;216(3-4):119-42.
56. Lim T-G, Lee S-Y, Huang Z, Chen H, Jung SK, Bode AM, et al. Curcumin suppresses proliferation of colon cancer cells by targeting CDK2. Cancer Prev Res. 2014;7(4):466-74.
57. Srivastava RK, Chen Q, Siddiqui I, Sarva K, Shankar S. Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclindependent kinase inhibitor p21/WAF1/CIP1. Cell Cycle. 2007;6(23):2953-61.
58. Choi BH, Kim CG, Bae Y-S, Lim Y, Lee YH, Shin SY. p21Waf1/ Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression. Cancer Res. 2008;68(5):1369-77.
59. Krishnaraju K, Nguyen HQ, Liebermann DA, Hoffman B. The zinc finger transcription factor Egr-1 potentiates macrophage differentiation of hematopoietic cells. Mol Cell Biol. 1995;15(10): 5499-507.
60. Krones-Herzig A, Mittal S, Yule K, Liang H, English C, Urcis R, et al. Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Res. 2005;65(12):5133-43.
61. Mazumder S, DuPree E, Almasan A. A dual role of cyclin E in cell proliferation and apotosis may provide a target for cancer therapy. Curr Cancer Drug Targets. 2004;4(1):65-75.
62. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347(20):1566-75.
63. Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G. Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol. 2007;73(7):1024-32.
64. Lee DS, Lee MK, Kim JH. Curcumin induces cell cycle arrest and apoptosis in human osteosarcoma (HOS) cells. Anticancer Res. 2009;29(12):5039-44.
65. Park MJ, Kim EH, Park IC, Lee HC, Woo SH, Lee JY, et al. Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. Int J Oncol. 2002;21(2):379-83.
66. Choudhuri T, Pal S, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem. 2005;280(20): 20059-68.
67. Li X, Kikuchi K, Takano Y. ING genes work as tumor suppressor genes in the carcinogenesis of head and neck squamous cell carcinoma. J Oncol. 2010;2011:963614.
68. Wang Y, Wang T, Han Y, Wu H, Zhao W, Tong D, et al. Reduced ING4 expression is associated with the malignancy of human bladder. Urol Int. 2015;94(4):464-71.
69. Liu E, Wu J, Cao W, Zhang J, Liu W, Jiang X, et al. Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neuro-Oncol. 2007;85(3):263-70.
70. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333-9.
71. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304-17.
72. Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett. 2002;512(1-3):334-40.
73. Jee SH, Shen SC, Kuo ML, Tseng CR, Chiu HC. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. J Investig Dermatol. 1998;111(4):656-61.
74. Jiang MC, Yang-Yen HF, Yen JJY, Lin JK. Curcumin induces apoptosis in immortalized NIH 3 T3 and malignant cancer cell lines. Nutr Cancer. 1996;26(1):111-20.
75. Watson JL, Hill R, Yaffe PB, Greenshields A, Walsh M, Lee PW, et al. Curcumin causes superoxide anion production and p53-independent apoptosis in human colon cancer cells. Cancer Lett. 2010;297(1):1-8.
76. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med. 2006;38(3):200-11.
77. Adjei AA. Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst. 2001;93(14):1062-74.
78. Cao AL, Tang QF, Zhou WC, Qiu YY, Hu SJ, Yin PH. Ras/ERK signaling pathway is involved in curcumin-induced cell cycle arrest and apoptosis in human gastric carcinoma AGS cells. J Asian Nat Prod Res. 2015;17(1):56-63.
79. Ono M, Higuchi T, Takeshima M, Chen C, Nakano S. Differential anti-tumor activities of curcumin against ras-and src-activated human adenocarcinoma cells. Biochem Biophys Res Commun. 2013;436(2):186-91.
80. Kim M-S, Kang H-J, Moon A. Inhibition of invasion and induction of apoptosis by curcumin in H-ras-transformed MCF10A human breast epithelial cells. Arch Pharm Res. 2001;24(4):349-54.
81. Limtrakul PN, Anuchapreeda S, Lipigorngoson S, Dunn FW. Inhibition of carcinogen induced c-Ha-ras and c-fos proto-oncogenes expression by dietary curcumin. BMC Cancer. 2001;1(1):1.
82. Vara JÁF, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193-204.
83. Wyatt LA, Filbin MT, Keirstead HS. PTEN inhibition enhances neurite outgrowth in human embryonic stem cell-derived neuronal progenitor cells. J Comp Neurol. 2014;522(12):2741-55.
84. Polivka J, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2014;142(2):164-75.
85. Qiao Q, Jiang Y, Li G. Inhibition of the PI3K/AKT-NF-κB pathway with curcumin enhanced radiation-induced apoptosis in human Burkitt’s lymphoma. J Pharmacol Sci. 2013;121(4):247-56.
86. Yu S, Shen G, Khor TO, Kim J-H, Kong A-NT. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther. 2008;7(9):2609-20.
87. Akkoç Y, Berrak Ö, Arısan ED, Obakan P, Çoker-Gürkan A, Palavan-Ünsal N. Inhibition of PI3K signaling triggered apoptotic potential of curcumin which is hindered by Bcl-2 through activation of autophagy in MCF-7 cells. Biochem Pharmacol. 2015;71: 161-71.
88. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012;4(5):a008052.
89. Morin PJ. β-catenin signaling and cancer. BioEssays. 1999;21(12):1021-30.
90. Kim HJ, Park SY, Park OJ, Kim YM. Curcumin suppresses migration and proliferation of Hep3B hepatocarcinoma cells through inhibition of the Wnt signaling pathway. Mol Med Rep. 2013;8(1):282-6.
91. Leow P-C, Bahety P, Boon CP, Lee CY, Tan KL, Yang T, et al. Functionalized curcumin analogs as potentmodulators of theWnt/ β-catenin signaling pathway. Eur J Med Chem. 2014;71:67-80.
92. Kolb TM, Davis MA. The tumor promoter 12-Otetradecanoylphorbol 13-acetate (TPA) provokes a prolonged morphologic response and ERK activation in Tsc2-null renal tumor cells. Toxicol Sci. 2004;81(1):233-42.
93. Libermann TA, Zerbini LF. Targeting transcription factors for cancer gene therapy. Curr Gene Ther. 2006;6(1):17-33.
94. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005;446(5):475-82.
95. Mishra A, Kumar R, Tyagi A, Kohaar I, Hedau S, Bharti AC et al. Curcumin modulates cellular AP-1, NF-kB, and HPV16 E6 proteins in oral cancer. ecancermedicalscience. 2015;9.
96. Singh S, Aggarwal BB. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). J Biol Chem. 1995;270(42):24995-5000.
97. Marín YE, Wall BA, Wang S, Namkoong J, Martino JJ, Suh J, et al. Curcumin downregulates the constitutive activity of NF-κB and induces apoptosis in novel mouse melanoma cells.Melanoma Res. 2007;17(5):274-83.
98. Marquardt JU, Gomez-Quiroz L, Camacho LOA, Pinna F, Lee YH, Kitade M, et al. Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer. J Hepatol. 2015;63(3):661-9.
99. Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D. STAT inhibitors for cancer therapy. J Hematol Oncol. 2013;6(1):1-11.
100. Lavecchia A, Di Giovanni C, Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr Med Chem. 2011;18(16):2359-75.
101. Yu H, Jove R. The STATs of cancer—new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97-105.
102. Blasius R, Reuter S, Henry E, Dicato M, Diederich M. Curcumin regulates signal transducer and activator of transcription (STAT) expression in K562 cells. Biochem Pharmacol. 2006;72(11): 1547-54.
103. Saydmohammed M, Joseph D, Syed V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J Cell Biochem. 2010;110(2):447-56.
104. Aggarwal BB, Surh Y-J, Shishodia, S. The molecular targets and therapeutic uses of curcumin in health and disease. Springer Science & Business Media; 2007.
105. Ferreira LC, Arbab AS, Jardim-Perassi BV, Borin TF, Gonçalves NN, Nadimpalli RSV, et al. Abstract A02: effect of curcumin on the tumor growth and angiogenesis of breast cancer. Cancer Res. 2015;75(1 Supplement):A02-A.
106. Chakraborty G, Jain S, Kale S, Raja R, Kumar S, Mishra R, et al. Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol Med Rep. 2008;1(5):641-6.
107. Yoysungnoen P, Wirachwong P, Changtam C, Suksamrarn A, Patumraj S. Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice. World J Gastroenterol. 2008;14(13):2003.
108. Arbiser JL, Klauber N, Rohan R, van Leeuwen R, Huang M-T, Fisher C, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med. 1998;4(6):376.
109. Arbiser J. Antiangiogenic therapy and dermatology: a review. Med Actual. 1997;33(10):687-96.
110. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895-904.
111. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275-92.
112. Woo MS, Jung SH, Kim SY, Hyun JW, Ko KH, Kim WK, et al. Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochem Biophys Res Commun. 2005;335(4):1017-25.
113. Radhakrishnan VM, Kojs P, Young G, Ramalingam R, Jagadish B, Mash EA, et al. pTyr 421 cortactin is overexpressed in colon cancer and is dephosphorylated by curcumin: involvement of nonreceptor type 1 protein tyrosine phosphatase (PTPN1). PLoS One. 2014;9(1):e85796.
114. Killian PH, Kronski E, Michalik KM, Barbieri O, Astigiano S, Sommerhoff CP, et al. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and-2. Carcinogenesis. 2012;33(12):2507-19.